ANGLE PLC Raises $30M to Commercialize Liquid Biopsy for Ovarian Cancer
ANGLE PLC raised $30M from new and existing investors to commercialize its Parsortix liquid biopsy for ovarian cancer as well as to support its filing with the US Food and Drug Administration.